Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) fell 0.5% during mid-day trading on Wednesday . The company traded as low as $1.78 and last traded at $1.87. 260,564 shares were traded during mid-day trading, a decline of 59% from the average session volume of 634,120 shares. The stock had previously closed at $1.88.
Analyst Ratings Changes
A number of brokerages recently commented on CLYM. Leerink Partnrs raised shares of Climb Bio to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners started coverage on shares of Climb Bio in a report on Monday, December 2nd. They set an "outperform" rating and a $10.00 price target on the stock.
Get Our Latest Stock Analysis on Climb Bio
Climb Bio Price Performance
The stock has a market capitalization of $122.34 million, a P/E ratio of -0.85 and a beta of -0.25. The stock has a 50-day moving average price of $2.33.
Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter. As a group, analysts anticipate that Climb Bio, Inc. will post -1.57 earnings per share for the current year.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Read More
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
